GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioDelivery Sciences International Inc (NAS:BDSI) » Definitions » ROE %

BioDelivery Sciences International (BioDelivery Sciences International) ROE % : 164.56% (As of Dec. 2021)


View and export this data going back to 2002. Start your Free Trial

What is BioDelivery Sciences International ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BioDelivery Sciences International's annualized net income for the quarter that ended in Dec. 2021 was $255.6 Mil. BioDelivery Sciences International's average Total Stockholders Equity over the quarter that ended in Dec. 2021 was $155.3 Mil. Therefore, BioDelivery Sciences International's annualized ROE % for the quarter that ended in Dec. 2021 was 164.56%.

The historical rank and industry rank for BioDelivery Sciences International's ROE % or its related term are showing as below:

BDSI' s ROE % Range Over the Past 10 Years
Min: -957   Med: -87.52   Max: 66.13
Current: 66.13

During the past 13 years, BioDelivery Sciences International's highest ROE % was 66.13%. The lowest was -957.00%. And the median was -87.52%.

BDSI's ROE % is not ranked
in the Drug Manufacturers industry.
Industry Median: 4.385 vs BDSI: 66.13

BioDelivery Sciences International ROE % Historical Data

The historical data trend for BioDelivery Sciences International's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioDelivery Sciences International ROE % Chart

BioDelivery Sciences International Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only Negative Equity -175.39 -30.76 28.89 57.33

BioDelivery Sciences International Quarterly Data
Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.96 19.30 32.55 22.54 164.56

Competitive Comparison of BioDelivery Sciences International's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, BioDelivery Sciences International's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioDelivery Sciences International's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioDelivery Sciences International's ROE % distribution charts can be found below:

* The bar in red indicates where BioDelivery Sciences International's ROE % falls into.



BioDelivery Sciences International ROE % Calculation

BioDelivery Sciences International's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=84.86/( (108.234+187.822)/ 2 )
=84.86/148.028
=57.33 %

BioDelivery Sciences International's annualized ROE % for the quarter that ended in Dec. 2021 is calculated as

ROE %=Net Income (Q: Dec. 2021 )/( (Total Stockholders Equity (Q: Sep. 2021 )+Total Stockholders Equity (Q: Dec. 2021 ))/ count )
=255.56/( (122.775+187.822)/ 2 )
=255.56/155.2985
=164.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2021) net income data. ROE % is displayed in the 30-year financial page.


BioDelivery Sciences International  (NAS:BDSI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2021 )
=Net Income/Total Stockholders Equity
=255.56/155.2985
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(255.56 / 172.616)*(172.616 / 290.333)*(290.333 / 155.2985)
=Net Margin %*Asset Turnover*Equity Multiplier
=148.05 %*0.5945*1.8695
=ROA %*Equity Multiplier
=88.02 %*1.8695
=164.56 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2021 )
=Net Income/Total Stockholders Equity
=255.56/155.2985
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (255.56 / 30.052) * (30.052 / 36.208) * (36.208 / 172.616) * (172.616 / 290.333) * (290.333 / 155.2985)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 8.5039 * 0.83 * 20.98 % * 0.5945 * 1.8695
=164.56 %

Note: The net income data used here is four times the quarterly (Dec. 2021) net income data. The Revenue data used here is four times the quarterly (Dec. 2021) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


BioDelivery Sciences International ROE % Related Terms

Thank you for viewing the detailed overview of BioDelivery Sciences International's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioDelivery Sciences International (BioDelivery Sciences International) Business Description

Traded in Other Exchanges
N/A
Address
4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.
Executives
James Vollins officer: See Remarks C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARK LAKE AVE SUITE 225, RALEIGH NC 27607
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Broadfin Healthcare Master Fund Ltd director C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Kevin Kotler director C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Mary Theresa Coelho officer: See Remarks 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Jeffrey Allen Bailey director, officer: Chief Executive Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Todd C Davis director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
W. Mark Watson director 324 S. HYDE PARK AVENUE, STE 350, TAMPA FL 33606
Peter Greenleaf director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Broadfin Capital, Llc director 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott M. Plesha officer: See Remarks 1410 SMYTHE ST DANIEL ISLAND SC 29492
Odonnell Francis E Jr director BIODELIVERY SCIENCES INTERNATIONAL, INC, 4131 PARKLAKE AVENUE, SUITE #225, RALEIGH NC 27612
Herm Cukier director, officer: Chief Executive Officer C/O BIODELIVERY SCIENTES INT., INC. 4131 PARKLAKE AVE, SUITE 225 RALEIGH NC 27612
Thomas B Smith officer: Chief Medical Officer BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE SUITE 225, RALEIGH NC 27612